Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CTSA | P10619 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | CTRC | Q99895 | 1/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | BRS3 | P32247 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30614607 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2ECE1KDM4EALOX15TSHR | |
| SCHEMBL17049444 | 0.91 | MCL1 (0.55) | SMN1; SMN2ECE1ALDH1A1SCN10AMCL1 | |
| SCHEMBL17354389 | 0.86 | CTSA (0.48) | SMN1; SMN2ECE1CTSAALDH1A1CTRC | |
| SCHEMBL3207980 | 0.85 | KDM4E (0.59) | ECE1KDM4EALOX15TSHRACMSD | |
| SCHEMBL208097 | 0.85 | KDM4E (0.64) | ECE1KDM4EALOX15TSHRACMSD | |
| SCHEMBL5208768 | 0.83 | CTSA (0.47) | SMN1; SMN2ECE1KDM4ETDP1CTSA | |
| Hydrochloric Acid SCHEMBL29133274 | 0.83 | KDM4E (0.61) | ECE1KDM4EALOX15TSHRACMSD | |
| SCHEMBL2553456 | 0.83 | KDM4E (0.52) | SMN1; SMN2ECE1KDM4EALOX15TSHR | |
| SCHEMBL4901418 | 0.82 | ALDH1A1 (0.61) | SMN1; SMN2KDM4EALDH1A1CTRCGAA | |
| SCHEMBL1137226 | 0.82 | HSD17B14 (0.57) | ECE1KDM4EALOX15TSHRACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022125736-A1 | A TAUTOMERIC LIGAND ENABLES BIOMIMETIC C-H HYDROXYLATION WITH MOLECULAR OXYGEN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-06-16 | — | — | WO | disclosed |
| CN-102946882-B | Phenylalamine derivatives and as the purposes of non-peptide GLP-1-1 receptor modulators | ARGUSINA, INC. (US) | 2016-05-18 | — | — | CN | disclosed |
| US-8748412-B2 | Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators | ARGUSINA BIOSCIENCE INC. (KY) | 2014-06-10 | — | — | US | disclosed |
| CN-102946882-A | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators | ARGUSINA INC | 2013-02-27 | — | — | CN | disclosed |
| EP-2531198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | Argusina Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011097300-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011094890-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, GPR119 | SMN1; SMN2 3331/4885ECE1 550/4885KDM4E 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.